NEW ALZHEIMER'S DRUG

Eisai, Biogen start U.S. accelerated approval for new Alzheimer's drug

The Biogen/Eisai drug Aduhelm was the first Alzheimer's treatment to win approval in nearly 20 years, but the Food and Drug Administration's (FDA) controversial use of the accelerated approval process - which authorizes drugs for severe conditions without strong proof of a benefit to patients - has come under heavy fire.